PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25325779-11	2015	In vitro findings of efficient elimination of Tregs may give the basis for implementation of a clinical trial to investigate Treg depletion by administration of an anti-hCCR4 mAb to solid cancer patients.	treg	46-50	C-C motif chemokine receptor 4	Homo sapiens	169-174	
20537408-6	2010	Moreover, the CCR4 ligand CCL22 is secreted by glioblastomas and may explain the specific Treg accumulation seen in these tumors.	treg	90-94	C-C motif chemokine receptor 4	Homo sapiens	14-18	
32667798-5	2020	We have developed small molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME, and elicit anti-tumor responses as a single agent or in combination with immune checkpoint blockade.	treg	133-137	C-C motif chemokine receptor 4	Homo sapiens	48-52	
35222362-0	2022	FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.	treg	25-29	C-C motif chemokine receptor 4	Homo sapiens	85-89	
33243932-0	2020	Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4.	treg	59-63	C-C motif chemokine receptor 4	Homo sapiens	80-84	
33243932-4	2020	In preclinical and clinical studies, it has been suggested that tumor trafficking of Treg is mediated by CC chemokine receptor 4 (CCR4).	treg	85-89	C-C motif chemokine receptor 4	Homo sapiens	105-128	
33243932-4	2020	In preclinical and clinical studies, it has been suggested that tumor trafficking of Treg is mediated by CC chemokine receptor 4 (CCR4).	treg	85-89	C-C motif chemokine receptor 4	Homo sapiens	130-134	
33243932-6	2020	Hence, CCR4 antagonism has the potential to be an effective antitumor treatment by reducing the accumulation of Treg into the tumor microenvironment (TME).	treg	112-116	C-C motif chemokine receptor 4	Homo sapiens	7-11	
33243932-7	2020	METHODS: We developed in vitro and in vivo models to assess Treg migration and antitumor efficacy using a potent and selective CCR4 antagonist, CCR4-351.	treg	60-64	C-C motif chemokine receptor 4	Homo sapiens	127-131